UNSC calls for cease-fires to speed up Covid vaccinations

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. NEW YORK: The UN Security Council on Friday unanimously passed a resolution calling on all member states to support a "sustained humanitarian pause" to local conflicts, in order to allow for Covid-19 vaccinations.Resolution 2656, adopted unanimously by the 15-member council, will enable the vaccines, which COVAX began distributing on February 24, to reach those living in conflict areas.The resolution calls on all UN member states to fund the COVAX initiative in order to help developing countries access coronavirus vaccines; to cooperate on overcoming logistical barriers to equitable access, including the inclusion of vulnerable groups such as refugees in national vaccination programs; and to support local ceasefires so coronavirus vaccinations can actually take place in conflict zones.Ceasefires have been used to vaccinate vulnerable communities in the past. In 2001, a two-day pause in fighting in Afghanistan gave 35,000 health workers and volunteers the opportunity to vaccinate 5.7 million children under five against polio.The first deliveries of COVAX vaccines took place on February 24, with 600,000 doses of the AstraZeneca vaccine arriving in Ghana.Briefing journalists afterward, World Health Organization chief Tedros Adhanom Ghebreyesus argued that more could be done.While welcoming the historic resolution and upholding the importance of vaccine equity, he said that "concrete steps should be taken" to waive intellectual property rights to increase vaccine production "and get rid of this virus as soon as possible.""The virus has taken the whole world hostage," Tedros said. "The UN Security Council can do it if there is political will." To keep reading about UNSC calls for cease-fires to speed up Covid vaccinations, Click on the link. Seoul, Korea
http://dlvr.it/RtbRlj

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more